Diabetes specialist Novo Nordisk A/S put a positive spin on flat sales growth during the second quarter by saying it had used the period to widen its lead in the GLP-1 space, and that its obesity pipeline was progressing well.
The Denmark-based company gave a wide-ranging overview of its pipeline and evolving product mix on 6 August when presenting on...








